Weekly Research Analysts’ Ratings Updates for Progyny (PGNY)

A number of firms have modified their ratings and price targets on shares of Progyny (NASDAQ: PGNY) recently:

• 11/14/2024 – Progyny had its price target lowered by analysts at Barclays PLC from $30.00 to $17.00. They now have an “overweight” rating on the stock.
• 11/13/2024 – Progyny had its price target lowered by analysts at Canaccord Genuity Group Inc. from $18.00 to $17.00. They now have a “hold” rating on the stock.
• 11/13/2024 – Progyny had its “hold” rating reaffirmed by analysts at Truist Financial Co.. They now have a $19.00 price target on the stock, down previously from $26.00.
• 11/13/2024 – Progyny had its price target lowered by analysts at Bank of America Co. from $22.00 to $21.00. They now have a “buy” rating on the stock.
• 10/1/2024 – Progyny had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $25.00 price target on the stock.

Progyny Trading Up 1.4 %

PGNY traded up $0.21 during midday trading on Thursday, hitting $15.48. The company’s stock had a trading volume of 1,046,799 shares, compared to its average volume of 1,404,436. The firm has a market cap of $1.32 billion, a P/E ratio of 26.69, a PEG ratio of 1.82 and a beta of 1.44. The firm has a 50-day moving average price of $16.04 and a two-hundred day moving average price of $22.40. Progyny, Inc. has a 52-week low of $13.39 and a 52-week high of $42.08.

Progyny (NASDAQ:PGNY) last released its quarterly earnings data on Tuesday, November 12th. The company reported $0.11 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.26). The firm had revenue of $286.63 million during the quarter, compared to analyst estimates of $296.85 million. Progyny had a net margin of 5.03% and a return on equity of 11.36%. The business’s revenue for the quarter was up 2.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.16 earnings per share. On average, equities analysts expect that Progyny, Inc. will post 0.58 EPS for the current year.

Hedge Funds Weigh In On Progyny

A number of institutional investors have recently made changes to their positions in the business. Franklin Resources Inc. raised its position in shares of Progyny by 17.0% in the 3rd quarter. Franklin Resources Inc. now owns 48,248 shares of the company’s stock valued at $759,000 after purchasing an additional 7,003 shares in the last quarter. Tidal Investments LLC increased its holdings in shares of Progyny by 67.7% in the 3rd quarter. Tidal Investments LLC now owns 60,722 shares of the company’s stock valued at $1,018,000 after acquiring an additional 24,507 shares during the last quarter. Disciplined Growth Investors Inc. MN increased its holdings in shares of Progyny by 56.5% in the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 826,726 shares of the company’s stock valued at $13,856,000 after acquiring an additional 298,314 shares during the last quarter. Barclays PLC increased its holdings in shares of Progyny by 530.4% in the 3rd quarter. Barclays PLC now owns 706,157 shares of the company’s stock valued at $11,835,000 after acquiring an additional 594,140 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Progyny in the 3rd quarter valued at approximately $469,000. 94.93% of the stock is owned by institutional investors and hedge funds.

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.